Delving into the Latest Updates on Cat allergy immunotherapy(Circassia Group Plc) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

Cat allergen vaccine, Cat allergy immunotherapy, Cat-PAD

+ [3]

Target-

Action

modulators

Mechanism

Immunomodulators

Therapeutic Areas

Immune System DiseasesInfectious DiseasesEye Diseases+ [2]

Active Indication-

Inactive Indication

AsthmaCat allergy (disorder)Conjunctivitis+ [3]

Originator Organization

Niox Group Plc

Active Organization-

Inactive Organization

Circassia Ltd.

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

This article immunol. changes in peripheral blood samples obtained from individuals with allergic rhinitis (AR), triggered by exposure to cat allergen, who were receiving peptide immunotherapy.Ten cat-sensitized AR individuals received cat-peptide antigen desensitization peptide immunotherapy for AR; participants were treated with four intradermal injections (at 4-wk intervals) of 6 nmol Cat-PAD.In analyses of complete blood count (CBC) data, frequencies of immune cells neutrophils, lymphocytes, and monocytes at V3 were significantly different from at V1A.Lower expression of immune genes at V3 was associated with IL-2-, IL-4-, IL-6-, granulocyte-macrophage colony-stimulating factor and B-cell receptor signaling pathway-mediated signaling events; conversely, higher expression of immune genes at V3 was associated with T-cell receptor signaling in CD4+ and CD8+ T cells and IL-12-mediated signaling events.Five immune genes with significant gene expression patterns were identified: integrin subunit alpha E (ITGAE, CD103), CD180 (LY64), (NCAM1, CD56), C-C motif chemokine receptor 7 (CCR7, CD197), And leucine-rich repeat neuronal 3 (LRRN3).Cellular and genetic approaches in peripheral blood with NAC may identify predictors of treatment efficacy and better pheno- or endo-typing for precision medicine.

01 Oct 2013·Expert Opinion on Investigational DrugsQ2 · MEDICINE

Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis

Q2 · MEDICINE

Review

Author: Margitta Worm ; Deepan Patel ; Peter Socrates Creticos

INTRODUCTIONAllergic rhinoconjunctivitis is an increasingly common source of morbidity with sensitivity to cats accounting for 10-15% of the disease burden. Allergy to cats is a major risk factor for the development of asthma.AREAS COVEREDWithin the present manuscript, the current data on a novel therapeutic approach to treat cat allergy is reviewed. Cat Peptide Antigen Desensitisation (Cat-PAD) is a mixture of seven small peptides developed for the treatment of cat allergy. It is designed to induce immunological tolerance via binding to MHC class II on antigen presenting cells and interacting with regulatory T cells without triggering the cross-linking of IgE on mast cells and basophils. The peptide sequences are derived from the major cat allergen Fel d 1. The peptides have been selected to ensure a similar T cell response to that generated to whole cat dander in ex-vivo PBMC derived from cat allergic individuals. The size of the peptides is insufficient to induce cross-linking of IgE. Clinical data from a series of studies shows that Cat-PAD is able to significantly reduce allergic rhinoconjunctivitis symptoms after a short course of four injections over 12 weeks, and that the treatment effect is persistent lasting 2 years after the start of treatment.EXPERT OPINIONTaken together Cat-PAD is a novel, well tolerated and promising therapeutic approach to treat cat allergic patients. Data from the current international Phase III study will unravel whether the concept is also efficient and tolerable under daily life circumstances.

01 Jan 2013·Journal of Allergy and Clinical ImmunologyQ1 · MEDICINE

Fel d 1–derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study

Q1 · MEDICINE

Article

Author: Pascal Hickey ; Peter Couroux ; Paul Laidler ; Roderick P. Hafner ; Deepen Patel ; Anne Marie Salapatek ; Mark Larché

BACKGROUNDAllergic rhinoconjunctivitis is an increasingly common source of morbidity, with sensitivity to cats accounting for 10% to 15% of disease burden. Allergy to cats is also a major risk factor for the development of asthma.OBJECTIVESWe sought to probe the persistence of the treatment effect of a novel F el d 1-derived peptide antigen desensitization (Cat-PAD) 1 year after the start of treatment in subjects with cat allergy-induced rhinoconjunctivitis after standardized allergen challenge.METHODSIn a randomized, double-blind, placebo-controlled, parallel-group clinical trial, subjects attended an environmental exposure chamber in which they were exposed to cat allergen before and after treatment with 2 different regimens of Cat-PAD over a 3-month period. Clinical efficacy was assessed as a change in total rhinoconjunctivitis symptom scores 18 to 22 weeks and 50 to 54 weeks after the start of treatment.RESULTSTreatment with Cat-PAD showed greater efficacy with 4 administrations of a 6-nmol dose 4 weeks apart than with 8 administrations of a 3-nmol dose 2 weeks apart. The treatment effect of 6 nmol persisted 1 year after the start of treatment and was significantly different from that of 3 nmol (P = .0342) and placebo (P = .0104). The treatment effect was apparent on both nasal and ocular symptoms at 1 year.CONCLUSIONSA short course of Cat-PAD improves the ocular and nasal components of rhinoconjunctivitis symptoms in subjects with cat allergy, with the treatment effect persisting 1 year after the start of treatment.

100 Deals associated with Cat allergy immunotherapy(Circassia Group Plc)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cat allergy (disorder)	Phase 3	-	Circassia Ltd.	01 Feb 2014
Rhinoconjunctivitis	Phase 3	Belgium	Circassia Ltd.	01 Oct 2012
Rhinoconjunctivitis	Phase 3	Russia	Circassia Ltd.	01 Oct 2012
Rhinoconjunctivitis	Phase 3	United States	Circassia Ltd.	01 Oct 2012
Rhinoconjunctivitis	Phase 3	Slovakia	Circassia Ltd.	01 Oct 2012
Rhinoconjunctivitis	Phase 3	Hungary	Circassia Ltd.	01 Oct 2012
Rhinoconjunctivitis	Phase 3	Germany	Circassia Ltd.	01 Oct 2012
Rhinoconjunctivitis	Phase 3	Czechia	Circassia Ltd.	01 Oct 2012
Rhinoconjunctivitis	Phase 3	Canada	Circassia Ltd.	01 Oct 2012
Rhinoconjunctivitis	Phase 3	Poland	Circassia Ltd.	01 Oct 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01620762 (CTgov)	Phase 3	Rhinoconjunctivitis	1,408	Placebo	fzursdyroq(aieemnrigp) = rordrgbsox itjdaeorfh (fookwzprjq, ensecclqdg - nmzvqqnqyw) View more	-	14 May 2018
NCT02040844 (CTgov)	Phase 3	Cat allergy (disorder)	430	placebo (Cat-PAD Treatment 1 (1 Course))	iazepcazfm(enoutzuqah) = qxpmdmeifv tpvpciqiwm (okjyckikrq, nijsnbausb - pgiifcbmsi) View more	-	14 May 2018
NCT02040844 (CTgov)	Phase 3	Cat allergy (disorder)	430	Cat-PAD (Cat-PAD Treatment (2 Courses))	iazepcazfm(enoutzuqah) = ghiqunevxe tpvpciqiwm (okjyckikrq, lgbxobbyhj - cgmqljewny) View more	-	14 May 2018
ASCO2004	Phase 1/2	Multiple Myeloma	15	PAD combination	ziwpbhmrlx(otggkheqlb) = opxdxwsbuy atszvjnpvg (olwbwiklro ) View more	-	15 Jul 2004